White Paper
Concentration-QT Modeling: An Efficient Alternative for Clinical Development
Efficient, Regulatory-Ready Cardiac Safety Solutions for Phase 1 Clinical Trials
Nov 06, 2025
Discover how concentration–QT (C-QT) modeling is transforming clinical drug development in this insightful white paper from IQVIA. The paper explores C-QT modeling as an efficient, cost-effective alternative to traditional thorough QT (TQT) studies for evaluating cardiac safety and QT interval prolongation risk. Drawing on regulatory guidance, real-world case studies, and IQVIA’s extensive expertise, it details best practices for integrating C-QT analysis into early-phase trials, addresses regulatory considerations, and demonstrates how this approach accelerates decision-making, reduces development costs, and supports successful regulatory submissions. This paper is essential reading for clinical development teams seeking to optimize cardiac safety assessments and streamline the path to market for new therapeutics.

Related solutions

Contact Us